retatrutide parkinson's disease trial nct First phase 3 data, a Triumph of Science! tirzepatide parkinson's disease clinical trial
Description
Epub 2022/06/21
Viking Pharmaceuticals is also developing a drug that activates both the GLP-1 and GIP receptors
Putting the side-effects aside, the earlier reports are showing good but limited amount of weight loss
Bupropion can cause some people who were manic or depressed in the past to become manic or depressed again
Yen, Fu-Shun et al
The Medicare GLP-1 Bridge specifically covers the weight management indications, so Ozempic and Mounjaro are not part of the bridge program
